Amgen v. Apotex: Apotex’s Reply Brief Filed in Fed. Cir. Appeal

Amgen v. Apotex (pegfilgrastim)  •  Patent Dance  •  U.S. Biosimilar Litigation News

Apotex has filed its reply brief in Amgen v. Apotex, which is currently on appeal before the Federal Circuit.  The brief is available here.

As we covered previously, the district court granted Amgen a preliminary injunction to prevent Apotex from marketing its biosimilar pegfilgrastim product until 180 days after Apotex provides a post-FDA-licensure notice that it intends to begin commercial marketing of the biosimilar. Apotex appealed this decision to the Federal Circuit.

Apotex filed its opening brief on December 30, 2015.

Amgen filed its response on February 4, 2016.

Stay tuned for further coverage

Download PDF

Comments are closed.